Intellia Therapeutics (NASDAQ:NTLA) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a sell rating in a research note published on Saturday.

NTLA has been the topic of a number of other research reports. Sanford C. Bernstein set a $14.50 price target on Intellia Therapeutics in a research report on Tuesday, October 28th. Royal Bank Of Canada reduced their target price on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating on the stock in a report on Friday. Guggenheim lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, October 27th. Chardan Capital dropped their price target on shares of Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Bank of America decreased their price objective on shares of Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Twelve investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics has an average rating of “Hold” and a consensus target price of $18.70.

Intellia Therapeutics Price Performance

NTLA opened at $9.73 on Friday. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The company’s 50 day moving average price is $17.16 and its two-hundred day moving average price is $12.54. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of -2.28 and a beta of 2.45.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The company had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. During the same quarter in the previous year, the business earned ($1.34) earnings per share. Intellia Therapeutics’s revenue was up 51.6% compared to the same quarter last year. As a group, equities research analysts predict that Intellia Therapeutics will post -5.07 EPS for the current year.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 1,871 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares in the company, valued at $960,523.08. The trade was a 3.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director William J. Chase purchased 100,000 shares of the firm’s stock in a transaction on Wednesday, August 20th. The stock was bought at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares of the company’s stock, valued at approximately $1,350,970.79. This represents a 288.24% increase in their position. The disclosure for this purchase is available in the SEC filing. 3.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. grew its stake in Intellia Therapeutics by 51.7% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 19,726 shares of the company’s stock valued at $140,000 after acquiring an additional 6,722 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Intellia Therapeutics by 30.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 16,798 shares of the company’s stock worth $112,000 after purchasing an additional 3,935 shares in the last quarter. D.A. Davidson & CO. grew its position in Intellia Therapeutics by 76.2% in the 1st quarter. D.A. Davidson & CO. now owns 26,020 shares of the company’s stock valued at $185,000 after purchasing an additional 11,250 shares during the period. Envestnet Asset Management Inc. increased its stake in Intellia Therapeutics by 9.7% during the 1st quarter. Envestnet Asset Management Inc. now owns 73,150 shares of the company’s stock valued at $520,000 after purchasing an additional 6,496 shares in the last quarter. Finally, CWM LLC raised its holdings in Intellia Therapeutics by 904.2% during the first quarter. CWM LLC now owns 14,912 shares of the company’s stock worth $106,000 after buying an additional 13,427 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.